Complement Factor D

Complement Factor D

Complement Factor D 분자 정보

Molecule Name
Complement factor D
분자 별명
CFD,Adipsin,PFD,DF,Complement factor D
Drug Development Progress
임상 약물 수5
시판 약물 수1
최고 연구 개발 단계Approved
표적 별명
EC 3.4.21,EC 3.4.21');,C3 Convertase Activator,ADIPSIN,D Component Of Complement (Adipsin),PFD,Complement Factor D Preproprotein,Complement Factor D (Adipsin),EC 3.4.21.46,ADN,CFD,Properdin factor D,DF,Complement factor D,EC:3.4.21.46
분자 배경
Complement factor D (CFD) is also known as Adipsin, C3 convertase activator, Properdin factor D (PFD), which contains one peptidase S1 domain and belongs to the peptidase S1 family. CFD / Adipsin cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. CFD / Adipsin is a serine protease that stimulates glucose transport for triglyceride accumulation in fats cells and inhibits lipolysis. Defects in CFD / Adipsin are the cause of complement factor D deficiency which predisposes to invasive meningococcal disease.

Complement Factor D 제품 목록

Species
  • Human(2)
  • Cynomolgus / Rhesus macaque(1)
Tag
  • His Tag(2)
  • Fc Tag(1)
Host
  • HEK293(3)
Conjugate
  • Unconjugated(3)
Grade
  • RUO(3)
Low Endotoxin
  • No(3)
분자Cat. No.Product Name종Host구조순도Activity규격 및 가격
Complement Factor D
Human Complement Factor D / CFD Protein, Fc Tag
Human
HEK293
SDS-PAGE

$360.00

100ug
Complement Factor D
Human Complement Factor D / CFD Protein, His Tag (active enzyme)
Human
HEK293
SDS-PAGE
Enzyme

$360.00

50ug
Complement Factor D
Rhesus macaque / Cynomolgus Complement Factor D / CFD Protein, His Tag (active enzyme)
Cynomolgus / Rhesus macaque
HEK293
SDS-PAGE
Enzyme

$360.00

100ug
You Have Viewed 1-3 Of 3 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
VemircopanACH-0145228; ACH-5228; ALXN-2050Phase 1 ClinicalAchillion Pharmaceuticals Inc
Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Hepatic Insufficiency; Lupus Nephritis; Myasthenia Gravis; Renal Insufficiency
상세
ACH-5548ACH-5548; ACH-0145548Phase 1 ClinicalAchillion Pharmaceuticals Inc
Autoimmune Diseases
상세
BCX-9930BCX-9930Phase 1 ClinicalBiocryst Pharmaceuticals Inc
C3 glomerulopathy; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Hemoglobinuria, Paroxysmal
상세
BCX-10013BCX-10013Phase 1 ClinicalBiocryst Pharmaceuticals Inc
Hemoglobinuria, Paroxysmal
상세
ZoracopanALXN-2080Phase 1 ClinicalAlexion Pharmaceuticals Inc
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
DanicopanACH-4471; ACH-0144471; ACH-CFDIS; ALXN-2040ApprovedAchillion Pharmaceuticals IncVOYDEYA, VoydeyaJapanHemoglobinuria, ParoxysmalAlexion Pharmaceuticals Inc2024-01-18
C3 glomerulopathy; Coronavirus Disease 2019 (COVID-19); Geographic Atrophy; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Hemolysis; Hepatic Insufficiency
상세
Customer Reviews